227 related articles for article (PubMed ID: 27400708)
1. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
2. Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.
Spallanzani RG; Dalotto-Moreno T; Raffo Iraolagoitia XL; Ziblat A; Domaica CI; Avila DE; Rossi LE; Fuertes MB; Battistone MA; Rabinovich GA; Salatino M; Zwirner NW
Cancer Immunol Immunother; 2013 Dec; 62(12):1781-95. PubMed ID: 24114144
[TBL] [Abstract][Full Text] [Related]
3. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
4. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
5. CD11b+ Ly6Chi Ly6G- immature myeloid cells recruited in response to Salmonella enterica serovar Typhimurium infection exhibit protective and immunosuppressive properties.
Tam JW; Kullas AL; Mena P; Bliska JB; van der Velden AW
Infect Immun; 2014 Jun; 82(6):2606-14. PubMed ID: 24711563
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive CD11b+Ly6Chi monocytes in pristane-induced lupus mouse model.
Ma H; Wan S; Xia CQ
J Leukoc Biol; 2016 Jun; 99(6):1121-9. PubMed ID: 26657791
[TBL] [Abstract][Full Text] [Related]
8. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Fan R; Satilmis H; Vandewalle N; Verheye E; Vlummens P; Maes A; Muylaert C; De Bruyne E; Menu E; Evans H; Chantry A; De Beule N; Hose D; Törngren M; Eriksson H; Vanderkerken K; Maes K; Breckpot K; De Veirman K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650020
[TBL] [Abstract][Full Text] [Related]
9. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson A; Nakhlé J; Sundstedt A; Plas P; Bauchet AL; Pierron V; Bruetschy L; Deronic A; Törngren M; Liberg D; Schmidlin F; Leanderson T
J Immunother Cancer; 2015; 3():53. PubMed ID: 26673090
[TBL] [Abstract][Full Text] [Related]
10. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
Zoglmeier C; Bauer H; Noerenberg D; Wedekind G; Bittner P; Sandholzer N; Rapp M; Anz D; Endres S; Bourquin C
Clin Cancer Res; 2011 Apr; 17(7):1765-75. PubMed ID: 21233400
[TBL] [Abstract][Full Text] [Related]
11. Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Aug; 16(1):610. PubMed ID: 27502070
[No Abstract] [Full Text] [Related]
12. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells.
Helmersson S; Sundstedt A; Deronic A; Leanderson T; Ivars F
Am J Pathol; 2013 May; 182(5):1671-80. PubMed ID: 23506849
[TBL] [Abstract][Full Text] [Related]
14. Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus.
Clements DR; Sterea AM; Kim Y; Helson E; Dean CA; Nunokawa A; Coyle KM; Sharif T; Marcato P; Gujar SA; Lee PW
J Immunol; 2015 May; 194(9):4397-412. PubMed ID: 25825443
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
16. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
[TBL] [Abstract][Full Text] [Related]
17. Age-related expansion and increased osteoclastogenic potential of myeloid-derived suppressor cells.
Li Z; Zhao Y; Chen Z; Katz J; Michalek SM; Li Y; Zhang P
Mol Immunol; 2021 Sep; 137():187-200. PubMed ID: 34274794
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.
Schmid M; Zimara N; Wege AK; Ritter U
Eur J Immunol; 2014 Nov; 44(11):3295-306. PubMed ID: 25142017
[TBL] [Abstract][Full Text] [Related]
19. Targeting CXCR4-dependent immunosuppressive Ly6C
Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
[TBL] [Abstract][Full Text] [Related]
20. Ly6C
Kimball A; Schaller M; Joshi A; Davis FM; denDekker A; Boniakowski A; Bermick J; Obi A; Moore B; Henke PK; Kunkel SL; Gallagher KA
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1102-1114. PubMed ID: 29496661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
